title: Novel function for the p38-MK2 signaling pathway in circulating CD1c+ (BDCA-1+) myeloid dendritic cells from healthy donors and advanced cancer patients; inhibition of p38 enhances IL-12 whilst suppressing IL-10.
abstract: There is growing interest in myeloid (my) dendritic cells (DC) as an alternative to monocyte-derived DC (moDC) for immunotherapy. However, in contrast to moDC, little is known regarding the effect of malignancy on the function, abundance or use of intracellular signaling pathways in myDC. Understanding the molecular detail of circulating myDC is therefore important for future use in advanced cancer. Advanced cancer patients had similar numbers of circulating myDC to cancer-free patients and healthy individuals, and secreted similar levels of IL-1β, IL-6, IL-10, IL-12 and IL-23. However, myDC from some patients failed to secrete the Th1-cytokine IL-12. Surprisingly, inhibiting p38 (p38i) signaling (using BIRB0796 or SB203580) markedly increased IL-12 secretion by myDC. This is in complete contrast to what is established for moDC where inhibiting p38 ablates IL-12. Interestingly, this was specific to IL-12, since IL-10 was suppressed by p38i in both DC types. The opposing effect of p38i on IL-12 was evident at the transcriptional level and in both DC types was mediated through the p38-MK2 pathway but did not involve differential phosphorylation of the distal Rsk kinase. Importantly, where patient myDC did not secrete IL-12 (or after treatment with suppressive melanoma lysate), p38i restored IL-12 to normal levels. In contrast to p38, inhibiting the other MAPK pathways had similar consequences in both DC types. We show for the first time the differential use of a major intracellular signaling pathway by myDC. Importantly, there are sufficient circulating myDC in advanced cancer patients to consider development of adoptive immunotherapy.
authors.affiliation: Host:Tumour Interactions Group, Academic Unit of Clinical Oncology University of Nottingham, United Kingdom.
authors.forename: Hester A
authors.initials: HA
authors.lastname: Franks
authors.forename: Qunwei
authors.initials: Q
authors.lastname: Wang
authors.forename: Stephanie J
authors.initials: SJ
authors.lastname: Lax
authors.forename: Mary K
authors.initials: MK
authors.lastname: Collins
authors.forename: David
authors.initials: D
authors.lastname: Escors
authors.forename: Poulam M
authors.initials: PM
authors.lastname: Patel
authors.forename: Andrew M
authors.initials: AM
authors.lastname: Jackson
mesh_terms: D000328:Adult; D000368:Aged; D018949:Antigens, CD1 / Q000276:immunology*; D015153:Blotting, Western; D016022:Case-Control Studies; D003713:Dendritic Cells / Q000276:immunology*; D005260:Female; D006023:Glycoproteins / Q000276:immunology*; D006801:Humans; D016753:Interleukin-10 / Q000378:metabolism*; D018664:Interleukin-12 / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000276:immunology*; D016133:Polymerase Chain Reaction; D015398:Signal Transduction; D048051:p38 Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism*
chemical_list: D018949:Antigens, CD1; C437944:CD1C protein, human; D006023:Glycoproteins; D016753:Interleukin-10; D018664:Interleukin-12; D048051:p38 Mitogen-Activated Protein Kinases
keywords: IL-12; Th1; dendritic cell; p38; signaling
references.citation: Blood. 2002 Dec 15;100(13):4512-20
references.pmid: 12393628
references.citation: Blood. 2005 Mar 15;105(6):2465-72
references.pmid: 15546948
references.citation: Scand J Immunol. 2007 Jun;65(6):514-24
references.pmid: 17523943
references.citation: Blood. 2003 Sep 1;102(5):1753-63
references.pmid: 12738673
references.citation: Immunobiology. 2004;209(1-2):191-8
references.pmid: 15481153
references.citation: Clin Cancer Res. 2011 Apr 15;17(8):2474-83
references.pmid: 21292818
references.citation: Blood. 2008 Mar 15;111(6):3050-61
references.pmid: 18180378
references.citation: Anticancer Res. 2012 Jul;32(7):2439-53
references.pmid: 22753700
references.citation: Arthritis Rheum. 2011 Jan;63(1):84-95
references.pmid: 20967853
references.citation: Br J Pharmacol. 2006 Oct;149(4):393-404
references.pmid: 16953188
references.citation: J Biol Chem. 2011 Jul 1;286(26):23582-90
references.pmid: 21566115
references.citation: J Immunol Methods. 2004 Jan;284(1-2):73-87
references.pmid: 14736418
references.citation: Int J Cancer. 2008 Aug 1;123(3):623-32
references.pmid: 18478568
references.citation: J Invest Dermatol. 2003 Mar;120(3):390-9
references.pmid: 12603851
references.citation: Br J Cancer. 2003 Oct 20;89(8):1463-72
references.pmid: 14562018
references.citation: Blood. 2002 Aug 15;100(4):1362-72
references.pmid: 12149219
references.citation: Nat Immunol. 2008 Sep;9(9):1019-27
references.pmid: 18677317
references.citation: Eur J Pain. 2011 Nov;15(10):1040-8
references.pmid: 21576029
references.citation: Nature. 1998 Mar 19;392(6673):245-52
references.pmid: 9521319
references.citation: Clin Immunol. 2006 Jun;119(3):317-29
references.pmid: 16527545
references.citation: J Biol Chem. 2001 Oct 5;276(40):37692-9
references.pmid: 11477091
references.citation: Cancer Immunol Immunother. 2008 Nov;57(11):1589-97
references.pmid: 18322684
references.citation: Ann Rheum Dis. 2010 Jan;69 Suppl 1:i77-82
references.pmid: 19995751
references.citation: Biochem J. 2007 Dec 15;408(3):297-315
references.pmid: 17850214
references.citation: Clin Cancer Res. 2016 Mar 1;22(5):1095-102
references.pmid: 26581242
references.citation: Cancer Immunol Immunother. 2010 Oct;59(10):1573-82
references.pmid: 20204387
references.citation: Prostate. 2007 Jan 1;67(1):1-7
references.pmid: 17075798
references.citation: Nat Immunol. 2005 Aug;6(8):769-76
references.pmid: 15995707
references.citation: Arthritis Rheum. 2000 Nov;43(11):2501-12
references.pmid: 11083274
references.citation: N Engl J Med. 2011 Jun 30;364(26):2507-16
references.pmid: 21639808
references.citation: Nat Immunol. 2007 Nov;8(11):1227-35
references.pmid: 17906627
references.citation: Eur Respir J. 2008 Jan;31(1):62-9
references.pmid: 17959643
references.citation: Chest. 2011 Jun;139(6):1470-1479
references.pmid: 21652557
references.citation: Gastroenterology. 2010 Apr;138(4):1255-65, 1265.e1-9
references.pmid: 20080092
references.citation: J Immunol. 2001 Mar 15;166(6):3837-45
references.pmid: 11238627
references.citation: Int Immunol. 2004 Dec;16(12):1701-9
references.pmid: 15477228
references.citation: Immunology. 2011 Sep;134(1):60-72
references.pmid: 21718315
references.citation: Cell Res. 2005 Jan;15(1):11-8
references.pmid: 15686620
references.citation: Eur Cytokine Netw. 2010 Dec;21(4):319-28
references.pmid: 21112826
references.citation: J Immunol. 1999 Apr 1;162(7):3865-72
references.pmid: 10201904
references.citation: Prostate. 2006 Feb 1;66(2):180-92
references.pmid: 16173035
references.citation: J Pharmacol Exp Ther. 2008 Mar;324(3):921-9
references.pmid: 18056868
references.citation: Br J Cancer. 2012 Jan 3;106(1):92-8
references.pmid: 22134504
references.citation: J Immunol. 2003 Nov 15;171(10):4984-9
references.pmid: 14607893
references.citation: N Engl J Med. 2012 Nov;367(18):1694-703
references.pmid: 23020132
references.citation: Clin Invest Med. 2008;31(3):E150-9
references.pmid: 18544278
references.citation: J Immunol. 2013 Apr 1;190(7):3246-55
references.pmid: 23460736
references.citation: Nat Immunol. 2005 Aug;6(8):777-84
references.pmid: 16007092